Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Level 5 - mechanism / opinion, no new human data
Meeting summary and expert consensus review with no new empirical human cohort or trial data.
OpenAlex W2141925819 · doi:10.1200/jco.2009.25.5729
What was done
This article summarizes an international multidisciplinary meeting on male breast cancer sponsored by the National Institutes of Health Office of Rare Diseases and the National Cancer Institute. Experts across epidemiology, genetics, molecular pathology, health services research, clinical oncology, and patient advocacy conducted a comprehensive review of existing data comparing male and female breast cancer to outline future collaborative research strategies.
What was found
The abstract reports no quantitative results, statistical measures, or primary patient data. It notes that male breast cancer represents less than 1% of all breast cancer diagnoses worldwide, leaving treatment paradigms reliant on small single-institution studies with no established optimal therapy. The documented outcome is the creation of the International Male Breast Cancer Program by the Breast International Group and North American Breast Cancer Group to pool epidemiological datasets, clinical records, and tissue specimens.
Why it matters
Because male breast cancer is rare, individual centers cannot recruit sufficient sample sizes to establish evidence-based guidelines. This report establishes an international cooperative framework to aggregate biological samples and clinical registries necessary for future trial design.
Limits
The abstract contains no new experimental, epidemiological, or clinical trial data. Specific diagnostic or therapeutic recommendations discussed during the proceedings are not detailed in the text.
Cited by
- supports Studying male breast cancer cases aided in the identification of BRCA genes due to the rarity of breast cancer in men.